Breaking News Instant updates and real-time market news.

BLUE

bluebird bio

$60.35

-4.05 (-6.29%)

, JUNO

Juno Therapeutics

$20.05

-1.08 (-5.11%)

08:27
12/01/16
12/01
08:27
12/01/16
08:27

bluebird bio data looks 'impressive,' says Leerink

Leerink analyst Michael Schmidt notes that bluebird bio (BLUE) announced first clinical data from its ongoing Phase I study of anti-BCMA CAR-T product candidate "bb2121" in relapsed/refractory multiple myeloma, and says it looks 'impressive." While he cautions that the data is still "somewhat immature," the early results justify the high level of excitement around the potential of anti-BCMA CAR-T therapy in relapsed/ refractory myeloma, as several other companies including Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS) have stated plans to also develop anti-BCMA-CART product candidates. Schmidt reiterates an Outperform rating on bluebird bio's shares.

BLUE

bluebird bio

$60.35

-4.05 (-6.29%)

JUNO

Juno Therapeutics

$20.05

-1.08 (-5.11%)

KITE

Kite Pharma

$50.93

1.92 (3.92%)

NVS

Novartis

$68.76

-0.2 (-0.29%)

  • 01

    Dec

  • 01

    Dec

  • 01

    Dec

  • 03

    Dec

  • 03

    Dec

BLUE bluebird bio
$60.35

-4.05 (-6.29%)

11/29/16
PIPR
11/29/16
NO CHANGE
PIPR
Piper sees bluebird regaining 'mojo and momentum'
After hosting management for an investor dinner, Piper Jaffray analyst Joshua Schimmer sees bluebird bio regaining its "mojo and momentum." The analyst expects a "steady stream of positive updates and derisking" starting with BCMA CAR-T data update this week and extending into optimizing LentiGlobin's profile for sickle cell and betathal in 2017. Schimmer has an Overweight rating on bluebird shares with a $95 price target. The biotechnology company closed yesterday down 5% to $60.65.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Piper says CAR-T researchers must heed risks highlighted by Juno news
Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."
12/01/16
WELS
12/01/16
NO CHANGE
WELS
bluebird bio data positive, says Wells Fargo
After bluebird bio announced interim Phase 1 dose escalation data for its CAR T product bb2121 in patients with relapsed/refractory multiple myeloma, Wells Fargo says the data shows that the product provides "a profound benefit for patients exhausting available treatment options." Wells thinks that the product could be approved on an accelerated timetable, and it keeps an Outperform rating on the stock.
12/01/16
BMOC
12/01/16
NO CHANGE
BMOC
bluebird bio data 'impressive,' says BMO Capital
BMO Capital analyst Matthew Luchini says that bluebird bio's Phase I data for its bb2121 product in myeloma was "impressive." The analyst notes that the overall response rate was 78%, and he adds the product to his model for the company ,estimating peak sales of about $3.6B. However, he keeps a Market Perform rating on the shares, citing the approximately 25% increase in the stock in after-hours trading.
JUNO Juno Therapeutics
$20.05

-1.08 (-5.11%)

11/29/16
ADAM
11/29/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma benefits from program delays at Juno, says Canaccord
Canaccord analyst John Newman believes Kite Pharma (KITE) will benefit from the program delays at Juno Therapeutics (JUNO). Two deaths in Juno's Phase 2 ROCKET trial may prompt safety questions for its drug to be used in refractory NHL, which raises the upside potential for Kite when its presents its data at the ASH conference. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
11/28/16
LEER
11/28/16
NO CHANGE
Target $34
LEER
Outperform
Juno Therapeutics price target lowered to $34 from $45 at Leerink
Leerink analyst Michael Schmidt lowered his price target for Juno Therapeutics to $34 from $45 following news that the pivotal ROCKET trial of its JCAR015 product candidate in adult acute lymphocytic leukemia has been placed on a clinical hold due to safety concerns. The analyst believes the future of the program is now increasingly uncertain as the company's management is trying to better understand the therapeutic window of JCAR015, raising the question of whether it moved into a pivotal trial too fast. Schmidt reiterates an Outperform rating on the shares.
11/25/16
MAXM
11/25/16
NO CHANGE
Target $34
MAXM
Buy
Juno still has significant opportunity in 'no-option population,' says Maxim
Maxim analyst Jason McCarthy removed JCAR015 in adult ALL from his model for Juno Therapeutics after the company placed its ROCKET study on clinical hold for the second time following two additional patient deaths. Accordingly, the analyst lowered his price target on Juno shares to $34 from $50. However, McCarthy keeps a Buy rating on Juno shares, as he still believes CAR-T technology, and the company, has a "significant opportunity in the no-option population" and that regulators will agree when evaluating treatments intended to help patients that will otherwise die.
11/25/16
11/25/16
DOWNGRADE
Target $25

Hold
Juno Therapeutics downgraded to Hold at SunTrust
As previously reported, SunTrust analyst Peter Lawson downgraded Juno Therapeutics to Hold from Buy due to the reduced visibility and increased uncertainty that comes from the two additional deaths in the company's ROCKET trial of JCAR015. Citing the renewed issues with JCAR015, Lawson decreased his probability of success across the company's pipeline and lowered his price target for Juno shares to $25 from $48.
KITE Kite Pharma
$50.93

1.92 (3.92%)

10/10/16
ADAM
10/10/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma BLA filing still expected by year end, says Canaccord
Canaccord analyst John Newman noted Kite Pharma released 12 month update on Zuma-1 Phase 1, which showed durable efficacy and is encouraging despite coming from a small patient group. The analyst saw the release as a continuation of positive trends and expects a BLA filing by the end of 2016. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.
NVS Novartis
$68.76

-0.2 (-0.29%)

10/26/16
LEER
10/26/16
NO CHANGE
Target $80
LEER
Market Perform
Novartis price target lowered to $80 from $89 at Leerink
Leerink analyst Seamus Fernandez lowered his price target for Novartis to $80 from $89 after a "disappointing" Q3 performance despite bottom-line beat. The analyst reiterates a Market Perform rating on the shares.
11/10/16
ARGS
11/10/16
UPGRADE
ARGS
Buy
Novartis upgraded to Buy from Hold at Argus
11/10/16
11/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Priceline (PCLN) upgraded to Buy from Hold at Stifel while the firm upgraded Expedia (EXPE) to Hold from Sell. 2. IBM (IBM) upgraded to Buy from Neutral at BofA/Merrill with analyst Wamsi Mohan expecting 2017 profits to grow as earnings have stabilized and negative revisions are unlikely and expects tailwinds from moderating pace of investments and savings from restructuring efforts. 3. L-3 Communications (LLL) and Northrop Grumman (NOC) upgraded to Overweight from Equal Weight at Barclays while the firm upgraded Lockheed Martin (LMT) to Equal Weight from Underweight. 4. Microsoft (MSFT) upgraded to Neutral from Underweight at Atlantic Equities. 5. Novartis (NVS) upgraded to Buy from Hold at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/16
RHCO
11/30/16
NO CHANGE
RHCO
GlycoMimetics has positive read through from deal, says SunTrust
SunTrust analyst Yatin Suneja says that Novartis' (NVS) recent acquisition of Selexys Pharmaceuticals "provides further clinical and commercial validation for the selectin class of adhesion molecules as meaningful therapeutic targets." The analyst notes that the acquisition came after Selexys' SelG1, which utilizes a P-selectin antibody, showed positive Phase II data in sickle cell disease. GlycoMimetics (GLYC) develops selectin antagonists. The analyst expects interest in the name to accelerate as more data is announced. Suneja keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$366.48

-7.43 (-1.99%)

13:10
09/22/17
09/22
13:10
09/22/17
13:10
Options
Heavy trading in Tesla expiring options as the skid continues »

Heavy trading in Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

13:10
09/22/17
09/22
13:10
09/22/17
13:10
General news
Treasury Options Action: bullish call buying in block trade »

Treasury Options Action:…

13:07
09/22/17
09/22
13:07
09/22/17
13:07
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 9/22 Baker-Hughes…

RHHBY

Roche

$32.04

0.09 (0.28%)

13:07
09/22/17
09/22
13:07
09/22/17
13:07
Hot Stocks
Roche reports EU approval of Tecentriq in types of lung, bladder cancer »

Roche announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

JUNO

Juno Therapeutics

$41.62

-3.59 (-7.94%)

13:05
09/22/17
09/22
13:05
09/22/17
13:05
Options
Juno Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 22

    Sep

BHGE

Baker Hughes

$36.40

-0.18 (-0.49%)

13:04
09/22/17
09/22
13:04
09/22/17
13:04
Hot Stocks
Baker Hughes reports U.S. rig count down 1 to 935 rigs »

Baker Hughes reports the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 20

    Oct

NVLN

Novelion Therapeutics

13:03
09/22/17
09/22
13:03
09/22/17
13:03
Hot Stocks
Novelion unit Aegerion settles SEC fraud charges for $4.1M »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDS

Dillard's

$55.07

-0.2189 (-0.40%)

, JWN

Nordstrom

$46.62

0.34 (0.73%)

13:02
09/22/17
09/22
13:02
09/22/17
13:02
Periodicals
Dillard's mentioned in 'vague rumors' about attempting to go-private, Kass says »

Douglas Kass of TheStreet…

DDS

Dillard's

$55.07

-0.2189 (-0.40%)

JWN

Nordstrom

$46.62

0.34 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MMM

3M

$211.18

0.74 (0.35%)

13:02
09/22/17
09/22
13:02
09/22/17
13:02
Hot Stocks
3M files patent, trademark infringement lawsuit against Thunder Finish »

3M and 3M Innovative…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FOSL

Fossil

$8.79

-0.21 (-2.33%)

12:55
09/22/17
09/22
12:55
09/22/17
12:55
Options
Fossil put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:55
09/22/17
09/22
12:55
09/22/17
12:55
Conference/Events
Federal Reserve Bank of Dallas President participates in a conference »

Dallas Federal Reserve…

CMCSA

Comcast

$37.47

0.01 (0.03%)

, FOX

21st Century Fox

$26.33

-0.05 (-0.19%)

12:53
09/22/17
09/22
12:53
09/22/17
12:53
Hot Stocks
Box Office Battle: 'Kingsman' sequel, 'LEGO: Ninjago' look to dethrone 'It' »

After two straight…

CMCSA

Comcast

$37.47

0.01 (0.03%)

FOX

21st Century Fox

$26.33

-0.05 (-0.19%)

VIAB

Viacom

$27.40

-0.32 (-1.15%)

SNE

Sony

$37.43

-0.035 (-0.09%)

DIS

Disney

$98.83

-0.06 (-0.06%)

CMCSK

Comcast

FOXA

21st Century Fox

$26.76

-0.11 (-0.41%)

VIA

Viacom

$38.20

-0.05 (-0.13%)

LGF.B

Lionsgate

$30.36

0.215 (0.71%)

TWX

Time Warner

$102.71

0.22 (0.21%)

LGF.A

Lionsgate

$31.57

0.32 (1.02%)

CBS

CBS

$58.85

0.06 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

  • 29

    Sep

  • 22

    Oct

  • 26

    Oct

  • 02

    Nov

AAPL

Apple

$153.39

-2.68 (-1.72%)

, FSLR

First Solar

$48.76

-0.09 (-0.18%)

12:51
09/22/17
09/22
12:51
09/22/17
12:51
General news
On The Fly: Top stock stories at midday »

Stocks on Wall Street…

AAPL

Apple

$153.39

-2.68 (-1.72%)

FSLR

First Solar

$48.76

-0.09 (-0.18%)

FINL

Finish Line

$9.22

-0.21 (-2.23%)

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

W

Wayfair

$75.24

-6.51 (-7.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Oct

DDC

Dominion Diamond

$14.19

0.005 (0.04%)

12:49
09/22/17
09/22
12:49
09/22/17
12:49
Hot Stocks
Dominion Diamond receives court approval for plan with The Washington Companies »

Dominion Diamond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$249.20

-0.19 (-0.08%)

, VOO

Vanguard S&P 500 ETF

$228.89

-0.18 (-0.08%)

12:45
09/22/17
09/22
12:45
09/22/17
12:45
Technical Analysis
On The Fly: ETF fund flow highlights »

For the week inflows…

SPY

SPDR S&P 500 ETF Trust

$249.20

-0.19 (-0.08%)

VOO

Vanguard S&P 500 ETF

$228.89

-0.18 (-0.08%)

XLF

Financial Select Sector

$25.43

-0.035 (-0.14%)

XLV

Health Care Select Sector SPDR

$81.25

-0.33 (-0.40%)

IWM

iShares Trust Russell 2000 Index Fund

$144.18

0.49 (0.34%)

GLD

SPDR Gold Trust

$123.09

0.41 (0.33%)

VWO

Vanguard FTSE Emerging Markets ETF

$44.17

-0.285 (-0.64%)

TLT

iShares 20+ Year Treasury Bond Fund

$125.84

-0.07 (-0.06%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.33

-0.01 (-0.01%)

IVV

iShares Core S&P 500

$252.18

-0.184 (-0.07%)

VO

Vanguard Mid-Cap Index Fund

$145.73

0.12 (0.08%)

VB

Vanguard Small-Cap Index Fund

$138.57

0.3 (0.22%)

VBK

Vanguard Small-Cap Growth Index Fund

$150.14

0.12 (0.08%)

MDY

SPDR S&P MidCap 400 ETF

$321.08

0.75 (0.23%)

SCHA

Schwab U.S. Small-Cap ETF

$65.69

0.19 (0.29%)

SVXY

ProShares Short VIX Short-Term Futures

$89.22

-0.5004 (-0.56%)

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$93.37

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
09/22/17
09/22
12:45
09/22/17
12:45
General news
Breaking General news story  »

Week of 9/22 Baker-Hughes…

ROK

Rockwell Automation

$177.39

0.06 (0.03%)

12:40
09/22/17
09/22
12:40
09/22/17
12:40
Options
Defensive option play opened in Rockwell »

Defensive option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.35

0.01 (0.01%)

12:30
09/22/17
09/22
12:30
09/22/17
12:30
Options
One week put buyer in the iShares High Yield Bond ETF »

One week put buyer in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$64.11

-0.89 (-1.37%)

12:25
09/22/17
09/22
12:25
09/22/17
12:25
Options
Activision Blizzard call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
09/22/17
09/22
12:25
09/22/17
12:25
Conference/Events
FDIC to hold a teleconference »

The FDIC examination…

$NSD

NASDAQ Market Internals

12:17
09/22/17
09/22
12:17
09/22/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
09/22/17
09/22
12:16
09/22/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$144.20

0.51 (0.35%)

12:10
09/22/17
09/22
12:10
09/22/17
12:10
Options
300K puts trade in iShares Small Cap Fund driven by spread trades »

300K puts trade in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IP

International Paper

$55.69

-1.6 (-2.79%)

, WRK

WestRock

$55.41

-2.2 (-3.82%)

12:09
09/22/17
09/22
12:09
09/22/17
12:09
Recommendations
International Paper, WestRock, KapStone analyst commentary  »

International Paper…

IP

International Paper

$55.69

-1.6 (-2.79%)

WRK

WestRock

$55.41

-2.2 (-3.82%)

KS

KapStone

$21.62

-0.96 (-4.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$366.48

-7.43 (-1.99%)

, CSIQ

Canadian Solar

$15.86

-0.16 (-1.00%)

12:05
09/22/17
09/22
12:05
09/22/17
12:05
Hot Stocks
ITC finds injury to U.S. solar product makers, moves to remedy phase »

The U.S. International…

TSLA

Tesla

$366.48

-7.43 (-1.99%)

CSIQ

Canadian Solar

$15.86

-0.16 (-1.00%)

FSLR

First Solar

$48.76

-0.09 (-0.18%)

JASO

JA Solar

$7.85

-0.335 (-4.09%)

SUNEQ

SunEdison

$0.02

0.0005 (2.44%)

SPWR

SunPower

$7.37

-0.49 (-6.23%)

TSL

Trina Solar

YGE

Yingli Green Energy

$2.43

0.02 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.